Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria
Abstract
A microemulsion preconcentrate was formulated on the basis of solubility of artemether (ARM) in the various oily phases and surfactants and phase diagrams. Various solid adsorbents were evaluated for their ability yield solid microemulsion preconcentrates (NanOsorb-ARM). NanOsorb-ARM on dilution yielded microemulsion with average globule size of 183 nm and polydispersity index of 0.498 when determined using photon correlation spectroscopy. The antimalarial activity of NanOsorb-ARM, ARM solution and marketed ARM formulation (Larither) was evaluated in Plasmodium berghei infected mice as per Peter's four day protocol. The acute lethal dose and the subacute toxicity of NanOsorb-ARM were determined as per the method suggested in Organization for Economic Cooperation and Development (OECD) guidelines. The NanOsorb-ARM exhibited significantly higher antimalarial activity (P<0.05) as compared to the marketed formulation of artemether (Larither). Surprisingly, placebo NanOsorb also showed significantly higher antimalarial activity as compared to Larither indicating that excipients used for the formulation of NanOsorb may have antimalarial activity. Subacute toxicity studies demonstrated that NanOsorb-ARM is comparatively safer than artemether oily solution with respect to survival, gross pathology, hematology and serum biochemistry in mice of both the genders.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NanoAbsorb is a solid microemulsion pre-concentrate formulation that can safely deliver artemether with higher antimalarial efficacy in vivo than the marketed formulation Larither.
“NanoAbsorb is a solid microemulsion pre-concentrate formulation that can safely deliver the widely used drug artemether with higher antimalarial efficacy in vivo than the marketed formulation Larither 110 .”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [110]
Cites
Microemulsion-based media as novel drug delivery systems
Lawrence, M. J., & Rees, G. D. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00103-4 · Cited by 2,044 · see citing works
Antimalarial drug discovery: efficacy models for compound screening
Fidock, D. A., Rosenthal, P. J., Croft, S. L., Brun, R., & Nwaka, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1416 · Cited by 863 · see citing works
Greenwood, B. M., & Mutabingwa, T. K. (2002) · Nature · doi:10.1038/415670a · Cited by 632 · see citing works
Pharmacological Effects of Formulation Vehicles
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 590 · see citing works
Peters, W. (1975) · PubMed · Cited by 488 · see citing works
The chemotherapy of rodent malaria, XXII
Peters, W., Portus, J. H., & Robinson, B. L. (1975) · Annals of Tropical Medicine and Parasitology · doi:10.1080/00034983.1975.11686997 · Cited by 429 · see citing works
Date, A. A., & Nagarsenker, M. S. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.08.038 · Cited by 409 · see citing works
Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles☆
Date, A. A., Joshi, M. D., & Patravale, V. B. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.009 · Cited by 294 · see citing works
Self-citationGlycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting
Bhadra, D., Yadav, A. K., Bhadra, S., & Jain, N. K. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.01.026 · Cited by 280 · see citing works
Yüksel, N., Karataş, A., Özkan, Y., et al. (2003) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(03)00142-5 · Cited by 144 · see citing works
Oral solid gentamicin preparation using emulsifier and adsorbent
Ιtο, Y., Kusawake, T., Ishida, M., et al. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.017 · Cited by 133 · see citing works
Kumaratilake, L. M., Robinson, B. S., Ferrante, A., et al. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115678 · Cited by 127 · see citing works
Owais, M., Varshney, G. C., Choudhury, A., Chandra, S., & Gupta, C. M. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.180 · Cited by 104 · see citing works
Pharmacokinetics and bioavailability of oral and intramuscular artemether
Karbwang, J., Na‐Bangchang, K., Congpuong, K., Molunto, P., & Thanavibul, A. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050295 · Cited by 99 · see citing works
Clinical Pharmacokinetics of Artemether and Lumefantrine (Riamet??)
̈vre, G. L., & Thomsen, M. S. (1999) · Clinical Drug Investigation · doi:10.2165/00044011-199918060-00006 · Cited by 98 · see citing works
Krugliak, M., Deharo, E., Shalmiev, G., et al. (1995) · Experimental Parasitology · doi:10.1006/expr.1995.1097 · Cited by 88 · see citing works
Preparation and in vitro evaluation of solid dispersions of halofantrine
Abdul‐Fattah, A. M., & Bhargava, H. N. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00941-3 · Cited by 84 · see citing works
Barker, S. A., Yap, S. P., Yuen, K. H., et al. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00261-x · Cited by 83 · see citing works
Chimanuka, B., Gabriëls, M., Detaevernier, M. R., & Plaizier-vercammen, J. A. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(01)00611-2 · Cited by 77 · see citing works
Stensrud, G., Sande, S. A., Kristensen, S., & Smistad, G. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00338-0 · Cited by 74 · see citing works
Primaquine-loaded poly(lactide) nanoparticles: physicochemical study and acute tolerance in mice
Júnior, J. M. R., Fessi, H., Bories, C., Puisieux, F., & Devissaguet, J. P. (1995) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(95)04135-4 · Cited by 66 · see citing works
Karunajeewa, H., Reeder, J. C., Lorry, K., Dabod, E., Hamzah, J., Page‐Sharp, M., Chiswell, G. M., Ilett, K. F., & Davis, T. M. E. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.968-974.2006 · Cited by 48 · see citing works
Jeans, C. W., & Heard, C. M. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00215-x · Cited by 25 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721 · see citing works
Nanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520 · see citing works
Urban, P., & Fernandez-Busquets, X. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660292 · Cited by 39 · see citing works
- Authors
- Joshi, M., Pathak, S., Sharma, S., & Patravale, V.
- Affiliations
- Institute of Chemical Technology (IN)
- Tata Institute of Fundamental Research (IN)
- Corresponding author
- Patravale, Vandana
- Venue
- International Journal of Pharmaceutics
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 362
- Issue
- 1-2
- Pages
- 172-178
- ISSN
- 0378-5173 (ISSN-L)
- OpenAlex
- W2128204697
- Cited by
- 71
- References
- 23
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 3 · 2019: 1 · 2018: 5 · 2017: 9 · 2016: 8 · 2015: 1 · 2014: 4 · 2013: 8 · 2012: 1
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University Grants Commission
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- artemether, malaria treatment, antimalarial activity, Plasmodium berghei, toxicity, globule size
- MeSH terms
- Artemether, Animals, Antimalarials, Chromatography, High Pressure Liquid, Drug Carriers, Drug Compounding, Emulsions, Lethal Dose 50, Malaria, Male, Oils, Particle Size, Plasmodium berghei, Solubility, Surface-Active Agents, Toxicity Tests, Artemisinins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
